However, we are aware of pharmacogenetic tools that measure genetic variation in apolipoprotein E (APOE), a gene with potential risk implications for Alzheimer disease, as well as emerging tools that will employ genome and exome sequencing technology that have the capability of identifying disease-related mutations. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.